TB-500 (Thymosin Beta-4)

TB-500 is a peptide used to accelerate the healing of injuries that are slow, stalled, or systemic in nature, things like nagging tendon and ligament problems, muscle tears, joint pain, post-surgery recovery, and sometimes broader soft-tissue issues that don't sit in one spot. Where

BPC-157 is the local repair specialist, TB-500 is the systemic one: it travels widely, helps cells migrate to damaged areas, builds new blood vessels, and dampens inflammation across the body rather than concentrating in one place. The two are commonly stacked for that reason.

Deep-dive

Thymosin beta-4 is one of the most abundant proteins inside human cells, making up roughly 70-80% of all beta-thymosins in the body and reaching intracellular concentrations up to 0.5 mM. It's not a niche signalling molecule, it's part of the basic cellular machinery, present in nearly every tissue and concentrated heavily in platelets that aggregate at injury sites. That's how it was originally discovered as a wound-healing factor: platelets dump it into damaged tissue, and the surrounding cells respond.

The actin mechanism, in plain terms. Inside cells, Tβ4 is the main protein that holds onto free actin monomers (G-actin) and releases them when the cell needs to build its internal skeleton (F-actin filaments). Actin is what cells use to change shape, crawl, divide, and rebuild damaged structures. By controlling the pool of available actin, Tβ4 controls how quickly cells can migrate into a wound, how fast new blood vessels can sprout, and how effectively damaged tissue can be remodelled. The 2023 review in Current Protein & Peptide Science lays out the binding mode in detail: Tβ4 sits in a 1:1 ratio with G-actin, blocking polymerisation until the cell signals for release. The short TB-500 fragment (residues 17-23, sequence LKKTET) covers the actin-binding motif and reproduces most of this activity.

Outside the cell, it's a different story. When Tβ4 is released into the fluid around tissues (from platelets, dying cells, or injection), it does a long list of things that have nothing to do with actin sequestration. The diverse activities led to the protein being described as "moonlighting", a single protein with several unrelated jobs. Extracellular effects established across many animal and cell studies include: promoting angiogenesis (new blood vessel formation), accelerating keratinocyte and endothelial cell migration into wounds, upregulating laminin-5 and other matrix proteins, suppressing inflammatory cytokines (TNF-α, IL-1β, IL-6), reducing apoptosis in stressed cells, recruiting stem and progenitor cells to damaged areas, and increasing hair follicle stem cell activity. The 2016 Kleinman and Sosne review is the cleanest summary of the dermal repair work and the one to read if you want the primary review.

Hair growth was an accident. Philp et al. were studying dermal wound healing in mice and noticed hair growing faster around the wound edges in Tβ4-treated animals. Follow-up work showed Tβ4 induced hair growth on undamaged dorsal skin too, by activating follicle stem cells. This is one of the more reproducible animal findings and probably underpins the anecdotal reports of improved hair quality in long-term users.

Cardiac repair. A 2004 Nature paper from Bock-Marquette and colleagues showed Tβ4 protected cardiomyocytes after experimental heart attack in mice and improved cardiac function. Follow-up work by Paul Riley's group at Oxford showed Tβ4 can reactivate epicardial progenitor cells, dormant cells on the outside of the adult heart, and partially convert them into functional cardiac muscle. This is one of the more striking regenerative findings in modern cardiology and drove a Phase 2 trial of intravenous Tβ4 in acute myocardial infarction (RGN-352). The trial was suspended for non-safety reasons before completion, and the cardiac use case remains experimental. For practical purposes, no one is injecting TB-500 for heart repair, but it's the strongest mechanistic argument that the molecule does something real systemically.

Human wound-healing trials. This is where the strongest published human data lives. RegeneRx ran multiple Phase 2 trials with topically applied Tβ4 in chronic wounds:

• A European venous stasis ulcer trial in 72 patients across 8 sites in Italy and Poland used three escalating doses of topical Tβ4 over 84 days. Safety was comparable to placebo, with acceptable tolerability across all dose levels, and faster healing was reported in treated groups.

• Phase 2 trials in pressure ulcers and the rare blistering condition epidermolysis bullosa also showed accelerated repair with no significant safety signals.

• Eye-drop formulations (RGN-259) of Tβ4 were tested in dry eye disease and neurotrophic corneal defects, with reports of corneal epithelial healing and symptom improvement.

These trials used purified full-length Tβ4, not the LKKTET fragment, and all were industry-sponsored. The development programme stalled around the late 2010s when RegeneRx ran out of funding before completing Phase 3 work. No regulatory approval followed, but the trials establish that Tβ4 is well tolerated at the doses studied and accelerates repair in conditions that are notoriously slow to heal.

Tendon, ligament, and muscle, the bodybuilding and athletic case. Almost everyone using TB-500 today is using it for soft-tissue injury, but the published evidence here is almost entirely animal. Rat and rabbit models show faster healing of transected Achilles tendons, accelerated muscle regeneration after crush injury, and improved healing of ligament tears, mostly in the same dose range (around 100-300 μg/kg, equivalent to roughly 6-20 mg in a 70 kg human, much higher than typical recreational use). The mechanism is plausible (angiogenesis, cell migration, anti-inflammatory) and consistent with the wound-healing literature, but the human evidence in athletic injury is anecdotal. Most subjective reports describe a meaningful reduction in pain and stiffness over 2-4 weeks, with continued improvement in joint function and tendon health over 6-12 weeks. Reports are consistent enough across communities (powerlifting, BJJ, climbing, post-surgery recovery) to suggest something real is happening, but there's no controlled human trial to anchor it.

Stacking with

BPC-157. This is the most common pairing and the rationale is mechanistic. BPC-157 acts locally, with strong effects on the vascular endothelium near the injury site and on gut mucosa. TB-500 acts systemically, with broader effects on cell migration, distant tissue, and overall inflammation. People with focal injuries (a specific tendon, a known joint) often see results with BPC-157 alone. People with diffuse problems (multiple sites, chronic systemic inflammation, post-surgery recovery, autoimmune-flavoured joint pain) tend to find the combination more useful. The two have not been formally tested together in humans, but the stack is one of the most reported in injury-recovery contexts.

What the evidence does not show. No long-term safety data in healthy humans on injected Tβ4. No published human trials of the LKKTET fragment specifically. No head-to-head against standard physiotherapy or PRP injections. No pharmacokinetic data for the fragment in humans. Most subjective dosing protocols are extrapolated from rodent studies and bodybuilding-forum convention rather than clinical evidence. The cancer concern, that pro-angiogenic and pro-migratory factors could theoretically support tumour growth, is mechanistically real but unproven in human use.

Women. TB-500 has no significant hormonal interactions. It doesn't affect the HPG axis, oestrogen, progesterone, or thyroid output, so dosing doesn't change across the menstrual cycle and doesn't conflict with hormonal contraception. The wound-healing literature was conducted in mixed-sex animal models and the Phase 2 venous ulcer trial included both sexes with no sex-specific safety findings. Two practical notes. First, oestrogen independently upregulates wound healing, collagen synthesis, and angiogenesis, so women in higher-oestrogen phases of life (pre-menopause, not post) start from a slightly more responsive baseline. Postmenopausal women may notice a more pronounced effect on skin texture and recovery for the same reason. Second, the hair-growth findings, while preliminary, apply to both sexes and may be particularly relevant for women with diffuse thinning, where the dermal-papilla and follicle stem cell mechanisms align with female pattern hair loss biology. Skip it in pregnancy and breastfeeding, no safety data.

Dosage:

• Loading phase: 2-2.5 mg twice weekly via subcutaneous injection for 4-6 weeks. This is the most commonly used protocol and tracks the rodent loading-dose pattern. Some people split this into smaller more frequent injections (e.g., 1 mg three times per week) for steadier plasma levels, the half-life is short but tissue effects are persistent

• Maintenance: 2-2.5 mg once weekly or every two weeks, for an additional 4-8 weeks if continued benefit is needed. Some protocols stop after the loading phase if the issue has resolved

• Localised injuries: Inject subcutaneously near the injured site for better local concentration. Tendon, ligament, and joint issues often respond to injection in the surrounding tissue. Avoid intra-tendinous injection, the goal is the surrounding fascia and subcutaneous tissue, not the structure itself

• Stacking with
  
  BPC-157: the most common combination for injury recovery. BPC-157 250-500 mcg daily covers local repair and vascular regrowth, TB-500 2 mg twice weekly covers systemic tissue migration and remodelling. The two are not antagonistic and have complementary mechanisms

• Cycle structure: Typical cycle is 4-6 weeks loading then 4-8 weeks maintenance, followed by an off-period of at least 4 weeks. Continuous long-term use is poorly studied and the theoretical cancer concern argues for periods off rather than indefinite dosing

• Reconstitution and storage: Reconstituted with bacteriostatic water (BAC), stable for about 4 weeks refrigerated. Lyophilised powder is stable at room temperature short-term but should be refrigerated for longer storage. Discard if cloudy or discoloured

• No hormonal interactions, no female-specific dose adjustment. Dosing is the same across sexes and is not affected by menstrual cycle, hormonal contraception, or HRT

Here's what you can expect:

Side effects & risks:

• Generally very well tolerated. Phase 2 trials with topical Tβ4 at doses up to several mg over 84 days reported safety comparable to placebo. Injected use in humans outside trials reports a similar pattern: side effects are uncommon and usually mild

• Injection site reactions: redness, mild swelling, occasional bruising. Rotating sites and using fresh needles minimises this

• Lethargy or sluggishness during the first week is the most consistent subjective report. Some users describe a mild brain-fog or flu-like feeling for 2-5 days at the start of a cycle, likely related to the systemic shift toward an anti-inflammatory state. Resolves on its own

• Headaches at higher doses or with rapid loading. Lower the dose or space injections further apart

• Vasodilation effects: mild flushing or warmth has been reported, particularly with larger doses. Drops in blood pressure are rare but possible, caution if you're already on antihypertensives or vasodilators

• Active cancer or recent cancer history, avoid. TB-500 promotes angiogenesis and cell migration, the same processes tumours use to grow and metastasise. The 2023 review notes Tβ4 has been associated with increased motility in some cancer cell lines. The mechanism is real even if the human risk in healing contexts is unproven. If you have any cancer history or unexplained lumps, skip this

• Pregnancy and breastfeeding, avoid. No safety data

• No hepatotoxicity, no renal toxicity, no hormonal suppression reported in human trials or animal toxicology. Tβ4 doesn't load the liver or kidneys, doesn't affect the HPG axis, doesn't suppress endogenous hormones

• WADA prohibited. TB-500 and thymosin beta-4 are banned under the S2 category (Peptide Hormones, Growth Factors, Related Substances, and Mimetics) of the WADA Prohibited List, in and out of competition. Metabolites are detectable in plasma and urine via LC-MS/MS methods. No Therapeutic Use Exemption is realistic. If you compete in tested sports, this is a hard no

• Source quality matters. TB-500 is unregulated and the grey market is full of underdosed, contaminated, and outright fake product. Compounded sources also vary in whether they're supplying the full Tβ4 peptide or just the LKKTET fragment, the labels are unreliable. Look for third-party Certificate of Analysis (COA) confirming sequence, purity, and concentration before injecting anything